U.S. License Holder:
Bristol-Myers Squibb
Date of License:
December-23-2005
Last Update:
Sep-30-2024
FDA-Approved Indications
ORENCIA (abatacept) is a selective T cell costimulation modulator indicated for:
The treatment of adult patients with moderately to severely active rheumatoid arthritis (RA);
The treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA);
The treatment of patients 2 years of age and older with active psoriatic arthritis (PsA);
The prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.